Friday 6-13-2014 Amgen Inc (AMGN) $AMGN opened at 116.67 hitting the high price of 116.69 and a day low of 115.30 with a total volume of 1,679,232. AMGN had a previous close of 116.20 and has been seeing an average volume of 2,631,635.
Overall Average: 0% Hold
Recent stock forum discussions about AMGN http://investorshangout.com/search?q=AMGN&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - Fri Jun 13, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Midday Glance: Biotechnology companies
AP - Fri Jun 13, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.: (full story)
Early Glance: Biotechnology companies
AP - Fri Jun 13, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.: (full story)
The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen
PR Newswire - Fri Jun 13, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the China Mobile Limited (NYSE:CHL-Free Report), China Petroleum and Chemical Corp. (NYSE:SNP-Free Report), Trina Solar Limited (NYSE:TSL-Free Report), AstraZeneca (NYSE:AZN-Free Report) andAmgen (Nasdaq:AMGN-Free Report). (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 4:10PM CDT
AstraZeneca (AZN) and partner Amgen (AMGN) announced that data from a phase II study evaluating the use of brodalumab in patients suffering from psoriatic arthritis was published in The New England Journal of Medicine. (full story)
InterMune Up On Bullish View Of U.S. Esbriet Launch
at Investor's Business Daily - Thu Jun 12, 11:57AM CDT
Biotech InterMune (ITMN) hit a three-year high on the stock market today after UBS lifted its price target for the company on bullish expectations for a drug launch. UBS analyst Andrew Peters wrote that he expects Esbriet to become the standard of... (full story)
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free. (full story)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell (full story)
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j7t8xn/neuro_endocrine) has announced the addition of the "Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Ipsen S.A. - Novartis AG - Progenics Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Camurus AB - Vascular Biogenics Ltd. - Advanced Accelerator Applications - Foresee Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/j7..._endocrine (full story)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell (full story)
Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs in 2013. Big drug companies, such as AbbVie, Johnson & Johnson , and Amgen , offer... (full story)
Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine
PR Newswire - Wed Jun 11, 4:00PM CDT
Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM). These data will also be presented at the 2014 European League Against Rheumatism (EULAR) Annual Congress in Paris on June 14, 2014 (10:15 a.m. CEST, Abstract No. SAT0404). Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. The IL-17 pathway plays a central role in inducing and promoting inflammatory disease processes. (full story)
Mantle Cell Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6jdmb/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Gilead Sciences, Inc. - Merck & Co., Inc. - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - ImmunoGen, Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Teva Pharmaceutical Industries Limited - Cell Therapeutics, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/p6...antle_cell (full story)
Overall Average: 0% Hold
Recent stock forum discussions about AMGN http://investorshangout.com/search?q=AMGN&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - Fri Jun 13, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Midday Glance: Biotechnology companies
AP - Fri Jun 13, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.: (full story)
Early Glance: Biotechnology companies
AP - Fri Jun 13, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.: (full story)
The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen
PR Newswire - Fri Jun 13, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the China Mobile Limited (NYSE:CHL-Free Report), China Petroleum and Chemical Corp. (NYSE:SNP-Free Report), Trina Solar Limited (NYSE:TSL-Free Report), AstraZeneca (NYSE:AZN-Free Report) andAmgen (Nasdaq:AMGN-Free Report). (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 4:10PM CDT
AstraZeneca (AZN) and partner Amgen (AMGN) announced that data from a phase II study evaluating the use of brodalumab in patients suffering from psoriatic arthritis was published in The New England Journal of Medicine. (full story)
InterMune Up On Bullish View Of U.S. Esbriet Launch
at Investor's Business Daily - Thu Jun 12, 11:57AM CDT
Biotech InterMune (ITMN) hit a three-year high on the stock market today after UBS lifted its price target for the company on bullish expectations for a drug launch. UBS analyst Andrew Peters wrote that he expects Esbriet to become the standard of... (full story)
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free. (full story)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell (full story)
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j7t8xn/neuro_endocrine) has announced the addition of the "Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Ipsen S.A. - Novartis AG - Progenics Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Camurus AB - Vascular Biogenics Ltd. - Advanced Accelerator Applications - Foresee Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/j7..._endocrine (full story)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell (full story)
Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs in 2013. Big drug companies, such as AbbVie, Johnson & Johnson , and Amgen , offer... (full story)
Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine
PR Newswire - Wed Jun 11, 4:00PM CDT
Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM). These data will also be presented at the 2014 European League Against Rheumatism (EULAR) Annual Congress in Paris on June 14, 2014 (10:15 a.m. CEST, Abstract No. SAT0404). Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. The IL-17 pathway plays a central role in inducing and promoting inflammatory disease processes. (full story)
Mantle Cell Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6jdmb/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Gilead Sciences, Inc. - Merck & Co., Inc. - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - ImmunoGen, Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Teva Pharmaceutical Industries Limited - Cell Therapeutics, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/p6...antle_cell (full story)
